Receptorpharmacological models for the therapy of labyrinthine vertigo

Acta Oto-Laryngologica

Volumn 116, Issue 2, 1996, Pages 189-191

  Ehrenberger, Klaus ^a   Felix, Dominik ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antivertiginous drugs; Excitatory GABA(A) receptor; Neurotoxicity; Vestibular imbalance; Vestibular neurotransmission

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; FLUMAZENIL;

ARTICLE; CASE REPORT; HUMAN; MALE; PRIORITY JOURNAL; VERTIGO;

EID: 0029960072     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.3109/00016489609137820     Document Type: Article

References (18)

1. Ehrenberger K, Felix D, Wyss U. Efferent controlled integrating functions of primary vestibular afferents. Acta Otolaryngol (Stockh) 1979; 87: 472-6.
2. Schwarz DWF, Schwarz IE, Hu K. Transmitter neurochemistry of the efferent neuron system innervating the labyrinth. J Otolaryngol 1989; 18: 28-31.
3. Anniko M, Arnold W. Acetylcholine receptor localization in human adult cochlear and vestibular hair cells. Acta Otolaryngol (Stockh) 1991; 111: 491-9.
4. Usami S, Matsubara A, Fujita S, Shinkawa H, Hayashi M. NMDA (NMDAR1) and AMPA-type (GluR2/3) receptor subunits are expressed in the inner ear. Neuro Report 1995; 6: 1161-4.
5. Lopez I, Wu JY, Meza G. Immunocytochemical evidence for an afferent GABAergic neurotransmission in the guinea pig vestibular system. Brain Res 1992; 589: 341-8.
6. Usami S, Hozawa J, Tazawa M, Jin H, Matsubara A, Fujita S. Localization of substance P-like immunoreactivity in guinea pig vestibular endorgans and the vestibular ganglion. Brain Res 1991; 555: 153-8.
7. Felix D, Ehrenberger K. The action of putative neurotransmitter substances in the mammalian labyrinth. In: Drescher DG, ed. Auditory biochemistry. Springfield: Thomas, 1985: 68-79.
8. Felix D, Felix H. Intracellular study of substance P in human Scarpa's ganglion cells. ORL 1995; 57: 15-7.
9. A similar-receptor-subtypes mediate excitatory neurotransmission in the mammalian labyrinth: an experimental and clinical study. In: Lubec G, Rosenthal GA, eds. Amino acids: chemistry, biology and medicine. Leiden: Escom, 1990: 337-44.
10. A receptors in the hippocampus. Science 1991; 253: 1420-3.
11. Staley K. Enhancement of the excitatory actions of GABA by barbiturates and benzodiazepines. Neurosci Lett 1992; 146: 105-7.
12. Erdö SL, Michler A. Wolff JR. GABA accelerates excitotoxic cell death in cortical cultures: protection by blockers of GABA-gated chloride channels. Brain Res 1991; 542: 254-8.
13. - ion channels modulated by multiple drug-binding sites. Trends Pharmacol Sci 1992; 13: 446-50.
14. Sieghart W. Subpopulations of benzodiazepine receptors: implications for the pharmacology of inverse agonists. In: Sarter M, Nutt DJ, Lister RG, eds. Benzodiazepine receptor inverse agonists. New York: Wiley-Liss, 1995: 1-24.
15. Duka T, Dorow R. Human experimental psychopharmacology of benzodiazepine receptor inverse agonists and antagonists. In: Sarter M, Nutt DJ, Lister RG, eds. Benzodiazepine receptor inverse agonists. New York: Wiley-Liss, 1995: 243-70.
16. Ehrenberger K, Benkoe E, Felix D. Suppressive action of picrotoxin, a GABA antagonist, on labyrinthine spontaneous nystagmus and vertigo in man. Acta Otolaryngol (Stockh) 1982; 93: 269-73.
17. Newcomb R, Palma A. Effects of diverse ω-conopeptides on the in vivo release of glutamic and γ-aminobutyric acids. Brain Res 1994; 638: 95-102.
18. Haefely WE, Martin JR, Grayson Richards J, Schoch P. The multiplicity of actions of benzodiazepine receptor ligands. Can J Psychiatry 1993; 38 (Suppl. 4): S104-8.